ArticleEClinicalMedicine2021

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial.

Shaukat Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.